Jeff is skilled in the development and implementation of cell and gene therapy for Fabry disease and cancer therapeutics. He has authored over 150 publications on gene therapy, viral-expressed transgenes, and biochemistry. Inventor on a number of patents. He was co-founder of Avrobio, Inc., which became a NASDAQ-traded public company focusing on Rare Disease gene therapy. He also founded Tundra Targeted Therapeutics, Inc., which is focusing on use of bispecific antibodies as immunotherapy treatments in CD30-positive cancers.